AmeriCredit Corp. Upgraded; Outlook Revised To Stable Mar 05

  • ID: 1802063
  • March 2005
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) March 22, 2005--Standard & Poor's Ratings Services said today that it raised its long-term counterparty credit rating on AmeriCredit Corp. to 'BB-' from 'B' and raised its unsecured debt rating to 'B+' from 'B'. The outlook was revised to stable from positive. "The upgrade recognizes the continued improvement in AmeriCredit's financial performance as shown by its good asset quality measures, improving liquidity position, strong balance sheet, and significant capital base," said Standard & Poor's credit analyst Lisa J. Archinow, CFA. The ratings incorporate the solid progress that the company has made in restructuring in accordance with its turnaround plan announced in February 2003. Since that time, AmeriCredit has effectively boosted loan originations to a more...

Companies mentioned in this report are: General Motors Financial Co. Inc.
Action: Outlook: Stable
Action: Upgraded

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

General Motors Financial Co. Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.